Skip to content

Effect of Dry Needling of Abdominal and Pelvic Floor Muscles in Chronic Functional Constipation

Effectiveness of Dry Needling of Abdominal and Pelvic Myofascial Trigger Points on Constipation Symptoms, Pelvic Floor Function, and Quality of Life in Women with Chronic Functional Constipation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180916041051N4
Enrollment
50
Registered
2026-05-17
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Functional Constipation. Constipation, Functional intestinal disorders

Interventions

Intervention 1: The intervention group will receive pelvic floor muscle biofeedback and dry needling of myofascial trigger points in the abdominal and pelvic muscles. Dry needling will be performed on

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Married women aged 20–50 years Diagnosis of Chronic functional constipation (CFC) confirmed by a colorectal specialist or gastroenterologist History of constipation symptoms for at least six months Presence of at least two myofascial trigger points in the abdominal and pelvic muscle groups , with at least one trigger point located in the pelvic floor muscles.

Exclusion criteria

Exclusion criteria: Pregnancy Presence of anal fissure History of anorectal surgery Constipation associated with alternating diarrhea Needle phobia (belonephobia) Diagnosed depression and/ or anxiety requiring pharmacological treatment Current use of oral or injectable anticoagulant or antiplatelet medications Presence of structural anorectal disorders requiring surgical intervention Diagnosed neurological disorders affecting bowel or pelvic floor function (e.g., multiple sclerosis, stroke, Parkinson’s disease, spinal cord injury) Change in constipation medication dosage within one month prior to enrollment Use of constipation-inducing medications (e.g., opioids) not discontinued at least two weeks before study enrollment Unwillingness or inability to provide informed consent Inability to comply with study procedures

Design outcomes

Primary

MeasureTime frame
Severity of Chronic Functional Constipation. Timepoint: It is checked at the baseline (before the intervention) and immediately after the final treatment session. Method of measurement: Persian version of Wexner Constipation Scoring System.

Secondary

MeasureTime frame
Pelvic floor muscle function (activity and strength). Timepoint: It is checked at the baseline (before the intervention) and immediately after the final treatment session. Method of measurement: Pelvic floor muscle function, encompassing both activity and strength, will be assessed. Muscle activity will be measured using electromyographic biofeedback, while muscle strength will be evaluated using the Modified Oxford Scale.;Quality of Life. Timepoint: It is checked at the baseline (before the intervention) and immediately after the final treatment session. Method of measurement: Persian version of Patient Assessment of Constipation Quality of Life (PAC QOL).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShabnam Shahali

Iran University of Medical Sciences

shabnamshahali@yahoo.com+98 21 2222 8051

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026